Table 2 Studies on allo-SCT versus... | American Society of Hematology

Table 2

Studies on allo-SCT versus chemotherapy in pediatric newly diagnosed AML without intention-to-treat analysis but with correction for time-to-transplantation

Group/study/patients	Period	Indication for allo-SCT in CR1	Age, y	Percentage of EFS/% of DFS	OS, %	Have a donor, %	Underwent allo-SCT, %	TRM, %
AIEOP LAM 87-92 trials¹¹	March 1982 to September 2001	All patients	< 15	5-y DFS	Not given	Not given	29* (LAM92)	Not given
Total, n = 388
Allo-SCT, n = 78				64 ± 6
Auto-SCT, n = 110				55 ± 5
Chemo, n = 89				28 ± 5
P				Not given
TCCSG AML M91-13 and AML M96-14³⁰	August 1991 to September 1998	All patients		5-y DFS	Not given	Not given	20†‡	Not given
Total, n = 170
Allo-SCT, n = 34				81 ± 19
Auto-SCT, n = 32
Chemo, n = 104				66 ± 10
P				.22
AML BFM87 and -93¹³	December 1986 to June 1998	HR patients	< 15	Not given	5-y OS	Not given	11
Total, n = 356
Allo-SCT, n = 39					62 ± 3			10
No allo-SCT, n = 317					64 ± 8			Not given
P					.40
LAME 89/91²¹	December 1988 to December 1998	All patients	< 20	5-y DFS	5-y OS	26* (LAME91)	26%* (LAME91)	Not given
Total, n = 244
Allo-SCT, n = 74				57 ± 7	71 ± 7
Chemo, n = 170				52 ± 4	55 ± 4
P				.18	.006

Group/study/patients	Period	Indication for allo-SCT in CR1	Age, y	Percentage of EFS/% of DFS	OS, %	Have a donor, %	Underwent allo-SCT, %	TRM, %
AIEOP LAM 87-92 trials¹¹	March 1982 to September 2001	All patients	< 15	5-y DFS	Not given	Not given	29* (LAM92)	Not given
Total, n = 388
Allo-SCT, n = 78				64 ± 6
Auto-SCT, n = 110				55 ± 5
Chemo, n = 89				28 ± 5
P				Not given
TCCSG AML M91-13 and AML M96-14³⁰	August 1991 to September 1998	All patients		5-y DFS	Not given	Not given	20†‡	Not given
Total, n = 170
Allo-SCT, n = 34				81 ± 19
Auto-SCT, n = 32
Chemo, n = 104				66 ± 10
P				.22
AML BFM87 and -93¹³	December 1986 to June 1998	HR patients	< 15	Not given	5-y OS	Not given	11
Total, n = 356
Allo-SCT, n = 39					62 ± 3			10
No allo-SCT, n = 317					64 ± 8			Not given
P					.40
LAME 89/91²¹	December 1988 to December 1998	All patients	< 20	5-y DFS	5-y OS	26* (LAME91)	26%* (LAME91)	Not given
Total, n = 244
Allo-SCT, n = 74				57 ± 7	71 ± 7
Chemo, n = 170				52 ± 4	55 ± 4
P				.18	.006

TCCSG indicates Tokyo Children's Cancer Study Group.

Percentage calculated from total group of patients.

†

Percentage calculated from patients who achieved CR and are eligible for random assignment.

‡

Twenty-four related donors, 8 unrelated donors, and 2 unrelated cord blood donors.

View Large

This Feature Is Available To Subscribers Only